kawasaki%20disease
KAWASAKI DISEASE
Kawasaki disease is an acute, febrile illness that is self-limited. It is a systemic vasculitic syndrome that primarily involves the medium- and small-sized muscular arteries of the body.
It is also known as mucocutaneous lymph node syndrome.
It affects primarily children <5 years old with peak incidence in 1-2 year of age.
The cause remains unknown but current research supports an infectious origin.
Epidemiological findings suggest that genetic predisposition and environmental factors play a role in the pathogenesis of the disease.

Kawasaki Disease References

  1. Chao B, Wang X, Wu L, et al. Diagnostic value of dual-source CT in Kawasaki disease. Chin Med J. 2010 Mar;123(6):670-674. PMID: 20368084
  2. De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007 Mar;11(5):301-308. http://www.ncbi.nlm.nih.gov/pubmed/?term=18074939. PMID: 18074939
  3. Freeman A, Shulman F, Stanford T. Kawasaki disease: summary of the American Heart Association guidelines. Am Fam Physician. 2006 Oct;74(7):1141-1148. http://www.aafp.org/afp/2006/1001/p1141.html. PMID: 17039750
  4. Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol. 2011 Jul;9:17. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163180/pdf/1546-0096-9-17.pdf. PMID: 21774801
  5. Kim DS. Kawasaki Disease. Yonsei Medl J. 2006 Dec;47(6):759-772. http://www.eymj.org/Synapse/Data/PDFData/0069YMJ/ymj-47-759.pdf. PMID: 17191303
  6. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008) [digest version]. Aug 18, 2010. Circ J. 2010 Sep;74(9):1989-2020. https://www.jstage.jst.go.jp/article/circj/74/9/74_CJ-10-74-0903/_pdf. PMID: 20724794
  7. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004 Oct;110(17):2747-2771. http://circ.ahajournals.org/content/110/17/2747.full.pdf. PMID: 15505111
  8. Yellen ES, Gauvreau K, Takahashi M, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Jan 25, 2010. Pediatrics. 2010 Feb;125(2):e234-e241. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896313/pdf/nihms209849.pdf. PMID: 20100771
  9. Son MB, Newburger JW. Kawasaki disease. In: Kliegman RM, Stanton BF, St Geme JW III, et al, eds. Nelson textbook of Pediatrics. 19th ed. Philadelphia, PA: Saunders, Elsevier; 2011.
  10. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  11. Sundel R. Kawasaki disease: Initial treatment and prognosis. UptoDate Web Site. http://www.uptodate.com/contents/search. Feb 2012. Accessed 09 Jul 2013.
  12. Sundel R. Treatment of refractory Kawasaki disease. UptoDate Web Site. http://www.uptodate.com/contents/treatment-of-refractory-kawasaki-disease. Jun 2013. Accessed 09 Jul 2013.
  13. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in kawasaki disease (JCS 2013). Circ J. 2014 Sep;78(10):2521-2562. https://www.jstage.jst.go.jp/article/circj/78/10/78_CJ-66-0096/_pdf. PMID: 25241888
  14. Research Committee of the Japanese Society of Pediatric Cardiology; Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int. 2014 Apr;56(2):135-158. doi: 10.1111/ped.12317. Accessed 15 Oct 2014. PMID: 24730626
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.